CL2023001195A1 - Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades. - Google Patents

Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades.

Info

Publication number
CL2023001195A1
CL2023001195A1 CL2023001195A CL2023001195A CL2023001195A1 CL 2023001195 A1 CL2023001195 A1 CL 2023001195A1 CL 2023001195 A CL2023001195 A CL 2023001195A CL 2023001195 A CL2023001195 A CL 2023001195A CL 2023001195 A1 CL2023001195 A1 CL 2023001195A1
Authority
CL
Chile
Prior art keywords
diseases
treatment
bicyclic compounds
compounds
compositions
Prior art date
Application number
CL2023001195A
Other languages
English (en)
Spanish (es)
Inventor
Leen Kawas
Kevin Church
Robert Taylor
Jewel Johnston
Douglas Boatman
Original Assignee
Athira Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Athira Pharma Inc filed Critical Athira Pharma Inc
Publication of CL2023001195A1 publication Critical patent/CL2023001195A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CL2023001195A 2020-11-02 2023-04-26 Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades. CL2023001195A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063108660P 2020-11-02 2020-11-02

Publications (1)

Publication Number Publication Date
CL2023001195A1 true CL2023001195A1 (es) 2023-10-20

Family

ID=81384389

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2023001195A CL2023001195A1 (es) 2020-11-02 2023-04-26 Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades.
CL2024000340A CL2024000340A1 (es) 2020-11-02 2024-02-02 Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2024000340A CL2024000340A1 (es) 2020-11-02 2024-02-02 Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades

Country Status (13)

Country Link
US (1) US20240025903A1 (cg-RX-API-DMAC7.html)
EP (1) EP4236944A4 (cg-RX-API-DMAC7.html)
JP (1) JP7884275B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230104191A (cg-RX-API-DMAC7.html)
CN (2) CN116568301A (cg-RX-API-DMAC7.html)
AR (1) AR124637A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021371026A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196582A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023001195A1 (cg-RX-API-DMAC7.html)
IL (1) IL302465A (cg-RX-API-DMAC7.html)
MX (1) MX2023004942A (cg-RX-API-DMAC7.html)
TW (1) TWI918751B (cg-RX-API-DMAC7.html)
WO (1) WO2022094400A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313039A (en) * 2021-12-17 2024-07-01 Athira Pharma Inc Uses of bicyclic compounds for the treatment of diseases
KR20250005323A (ko) * 2022-05-04 2025-01-09 아티라 파마, 인코포레이티드 신경병증을 치료하는 방법
US20250275976A1 (en) * 2022-05-04 2025-09-04 Athira Pharma, Inc. Methods of Treating Neuroinflammatory Conditions
JP2025538382A (ja) 2022-11-18 2025-11-28 アティラ・ファーマ・インコーポレイテッド 炎症病態を治療する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
WO2004035587A1 (en) 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
US7192976B2 (en) * 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2006036981A2 (en) * 2004-09-28 2006-04-06 Angion Biomedica Corp. Small molecule modulators of cytokine activity
US7879898B1 (en) * 2006-02-14 2011-02-01 Angion Biomedica Corp. Hepatocyte growth factor pathway activators in chronic obstructive pulmonary disease
EP1947085A1 (en) * 2007-01-19 2008-07-23 Laboratorios del Dr. Esteve S.A. Substituted indole sulfonamide compounds, their preparation and use as medicaments
US8691819B2 (en) * 2008-10-14 2014-04-08 Prism Biolab Corporation Alpha helix mimetic compositions for treating cancer and other CBP/catenin-mediated diseases and conditions
US20160074400A1 (en) * 2012-08-06 2016-03-17 University Of Southern California Wnt modulators for the protection, mitigation and treatment of radiation injury
EP3366687B1 (en) * 2015-09-18 2020-04-29 National University Corporation Tottori University Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis

Also Published As

Publication number Publication date
EP4236944A1 (en) 2023-09-06
TWI918751B (zh) 2026-03-21
CL2024000340A1 (es) 2024-08-16
CN116568301A (zh) 2023-08-08
US20240025903A1 (en) 2024-01-25
CN119684295A (zh) 2025-03-25
CA3196582A1 (en) 2022-05-05
AU2021371026A1 (en) 2023-06-15
JP2023550543A (ja) 2023-12-01
AU2021371026A9 (en) 2024-04-18
JP7884275B2 (ja) 2026-07-03
KR20230104191A (ko) 2023-07-07
AR124637A1 (es) 2023-04-19
IL302465A (en) 2023-06-01
TW202233622A (zh) 2022-09-01
MX2023004942A (es) 2023-07-06
EP4236944A4 (en) 2024-09-04
WO2022094400A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
CL2024000340A1 (es) Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades
CO2022002759A2 (es) Antagonistas de hpk1 y sus usos
CO2021007993A2 (es) Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina
MX2021007468A (es) Compuestos que participan en la union cooperativa y usos de los mismos.
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CL2020002573A1 (es) Inhibidores atf6 y sus usos.
DOP2020000040A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
PA8570701A1 (es) Compuestos que modulan la actividad de ppar y procedimientos para su preparacion
DOP2024000028A (es) Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
NI202000014A (es) Compuestos espirocíclicos y sus métodos de preparación y uso
MX2024013040A (es) Pirfenidona enriquecida con deuterio y metodos para su uso
CL2021002521A1 (es) Compuestos heteocíclicos y sus usos.
MX2022006862A (es) Inhibidores duales de magl y faah.
CO2023010940A2 (es) Compuestos moduladores de gcn2 y usos de los mismos
UY35472A (es) Compuestos y sus usos en la modulacion de la hemoglobina
CL2024003870A1 (es) Compuestos de degradación de wee1 y usos de los mismos
DOP2022000127A (es) Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismos.
MX2018009189A (es) Compuestos de anillo de siete miembros de pirimidina.
AR131235A1 (es) Formas cristalinas de n,n-dimetiltriptamina y métodos para usarlas
CL2025000272A1 (es) Derivados de arilo tricíclico y composiciones y métodos de los mismos
CL2025003186A1 (es) Moduladores de nk3 y usos de los mismos.
CL2024001748A1 (es) Usos de compuestos biciclicos para el tratamiento de enfermedades.
CO2022002808A2 (es) Proteínas de fusión nkg2d y sus usos
CL2022002589A1 (es) Tratamiento de trastornos respiratorios